Ключевые слова
Как цитировать
Аннотация
Ежегодно регистрируется более 250 тысяч смертей от злокачественных новообразований в россии и 8 миллионов в мире. Эффективность традиционных методов лечения, а также моноклональных антител и генной терапии лимитирована в случае резистентных форм и труднодоступной локализации опухоли. Лактоферрин (ЛФ) является универсальным белком с противораковой активностью, модулирует иммунный ответ и систему окислительно-восстановительных реакций организма, отличается кросс-видовой биосовместимостью. Благодаря способности взаимодействовать не только со специфическими рецепторами, но и с сигнальными, эн-доцитоза и TLR на различных типах клеток, лФ преодолевает гемотканевые барьеры. На моделях in vivo и in vitro подтверждена терапевтическая эффективность применения лактоферрина, продуктов его расщепления и синтетических пептидов при различных видах злокачественной пролиферации. В экспериментах продемонстрирована перспективность использования лФ как адьюванта перед химио- и радиотерапией, носителя при генной терапии рака. однако результаты клинических исследований малочисленны и требуют дальнейшего изучения.
Библиографические ссылки
Reale A., Vitiello A., Conciatori V. et al. Perspectives on immunotherapy via oncolytic viruses // Infect Agent Cancer. - 2019. - Vol. 14. - P. 5. - DOI: 10.1186/s13027-018-0218-1
Cao H., Xiao Z., Zhang Y et al. Dosimetric comparisons of different hypofractionated stereotactic radiotherapy techniques in treating intracranial tumors > 3 cm in longest diameter // J. Neurosurg. - 2019. - P. 1-9. - DOI: 10.3171/2018.12.JNS181578
Chea C., Miyauchi M., Inubushi T. et al. Molecular mechanism of inhibitory effects of bovine lactoferrin on the growth of oral squamous cell carcinoma // PLoS One. - 2018. - Vol. 13(1). - P. e0191683. - DOI: 10.1371/journal.pone.0191683
Lu Y., Zhang T.F., Shi Y. et al. PFR peptide, one of the antimicrobial peptides identified from the derivatives of lactoferrin, induces necrosis in leukemia cells // Sci. Rep. - 2016. - Vol. 6. - P. 20823. - DOI: 10.1038/srep20823
Gibbons J.A., Kanwar J.R., Kanwar R.K. Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer // BMC Cancer. - 2015. - Vol. 15. - P. 425. - DOI: 10.1186/s12885-015-1441-4
Levay P.F., Viljoen M. Lactoferrin: a general review // Haematologica. - 1995. - Vol. 80. - P. 252-267.
Siqueiros-Cendon T., Arévalo-Gallegos S., Iglesias-Figueroa B.F. et al. Immunomodulatory effects of lactoferrin // Acta Pharmacol Sin. - 2014. - Vol. 35(5). - P. 557-566. - DOI: 10.1038/aps.2013.200
Зорина В.Н., Зорин H.A. Белковые компоненты врожденного иммунитета в защите от патогенной инвазии // ЖМЭИ. - 2013. - Т. 3. - С. 111-117.
Actor J.K., Hwang S.A., Kruzel M.L. Lactoferrin as a natural immune modulator // Curr Pharm Des. - 2009. - Vol. 15(17). - P. 1956-1973.
Ebrahim F., Shankaranarayanan J.S., Kanwar J.R. et al. Identification of unprecedented anticancer properties of high molecular weight biomacromolecular complex containing bovine lactoferrin (HMW-bLf) // PLoS One. - 2014. - Vol. 9(9). - P. e106568. - DOI: 10.1371/journal.pone.0106568
Sharma S., Sinha M., Kaushik S. et al. C-lobe of lactoferrin: the whole story of the half-molecule // Biochem Res Int. - 2013. - Vol. 2013. - P. 271641. - DOI: 10.1155/2013/271641
Fischer R., Debbabi H., Blais A. et al. Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues // Int. Immunopharmacol. - 2007. - Vol. 7(10). - P. 1387-1393. - DOI: 10.1016/j.intimp.2007.05.019
Wu J., Yang L., Liu G. et al. Isolation and purification of recombinant human lactoferrin (rhLF) from transgenic rice and its antibacterial activities // Wei Sheng Yan Jiu. - 2013. - Vol. 42(3). - P. 399-404.
Zimecki M., Artym J., Kociçba M. et al. The effect of carbohydrate moiety structure on the immunoregulatory activity of lactoferrin in vitro // Cell Mol Biol Lett. -2014. - Vol. 19(2). - P. 284-296. - DOI: 10.2478/s11658-014-0196-2
Legrand D., Elass E., Carpentier M., Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci. 2005 Nov;62(22):2549-59.
Nishimura Y, Homma-Takeda S., Kim H.S., Kakuta I. Radioprotection of mice by lactoferrin against irradiation with sublethal X-rays // J. Radiat. Res. - 2014. - Vol. 55(2). - P. 277-282. - DOI: 10.1093/jrr/rrt117
Mader J.S., Salsman J., Conrad D.M., Hoskin D.W. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines // Mol. Cancer Ther. - 2005. - Vol. 4(4). - P. 612-624. - DOI: 10.1158/1535-7163.MCT-04-0077
Hilchie A.L., Vale R., Zemlak T.S., Hoskin D.W. Generation of a hematologic malignancy-selective membranolytic peptide from the antimicrobial core (RRWQWR) of bovine lactoferricin // Exp. Mol. Pathol. - 2013. - Vol. 95(2). - P. 192-198. - DOI: 10.1016/j.yex-mp.2013.07.006
Vargas Casanova Y, Rodriguez Guerra J.A., Umana Pérez YA. et al. Antibacterial Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Cytotoxic Effect against MDA-MB-468 and MDA-MB-231 Breast Cancer Cell Lines // Molecules. - 2017. - Vol. 22(10). - pii: E1641. - DOI: 10.3390/molecules22101641
Solarte V.A., Conget P., Vernot J.P et al. A tetrameric peptide derived from bovine lactoferricin as a potential therapeutic tool for oral squamous cell carcinoma: A preclinical model // PLoS One. - 2017. - Vol. 12(3). - P. e0174707. - DOI: 10.1371/journal.pone.0174707
Kanwar J.R., Palmano K.P., Sun X. et al. ‘Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy // Immunol Cell Biol. - 2008. - Vol. 86(3). - P. 277-288. - DOI: 10.1038/sj.icb.7100163
Shimamura M., Yamamoto Y, Ashino H. et al. Bovine lactoferrin inhibits tumor-induced angiogenesis. Int J Cancer. 2004; 111(1):111-6. DOI: 10.1002/ijc.20187
Pereira C.S., Guedes J.P., Gonçalves M., Loureiro L., Castro L., Geros H., Rodrigues L.R., Côrte-Real M. Lactoferrin selectively triggers apoptosis in highly metastatic breast cancer cells through inhibition of plasmalemmal V-H+-ATPase. Oncotarget. 2016; 7(38):62144-62158. DOI: 10.18632/oncotarget.11394
Pan W.R., Chen P.W., Chen YL. et al. Bovine lactoferricin B induces apoptosis of human gastric cancer cell line AGS by inhibition of autophagy at a late stage // J. Dairy Sci. - 2013. - Vol. 96(12). - P. 7511-7520. - DOI: 10.3168/jds.2013-7285
Shaheduzzaman S., Vishwanath A., Furusato B. et al. Silencing of Lactotransferrin expression by methylation in prostate cancer progression // Cancer Biol. Ther. - 2007. - Vol. 6(7). - P. 1088-1095.
Tsuda H., Sekine K., Fujita K., Ligo M. Cancer prevention by bovine lactoferrin and underlying mechanisms - a review of experimental and clinical studies // Biochem Cell Biol. - 2002. - Vol. 80(1). - P. 131-136.
Eliassen L.T., Haug B.E., Berge G., Rekdal O. Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications // J. Pept. Sci. - 2003. - Vol. 9(8). - P. 510-517.
Lim L.Y., Koh P.Y., Somani S. et al. Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes // Nanomedicine. - 2015. - Vol. 11(6). - P. 1445-1454. - DOI: 10.1016/j.nano.2015.04.006
Wang J., Li Q., Ou Y et al. Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer // Arch Pharm Res. - 2011. - Vol. 34(6). - P. 987-995. - DOI: 10.1007/s12272-011-0616-z
Shen Z., Liu T., Li Y. et al. Fenton-Reaction-Acceleratable Magnetic Nanoparticles for Ferroptosis Therapy of Orthotopic Brain Tumors // CS Nano. - 2018. - Vol. 12(11). - P. 11355-11365. - DOI: 10.1021/acsnano.8b06201
Roseanu A., Florian P.E., Moisei M. et al. Liposomalization of lactoferrin enhanced its anti-tumoral effects on melanoma cells // Biometals. - 2010. - Vol. 23(3). - P. 485-492. - DOI: 10.1007/s10534-010-9312-6
Furlong S.J., Mader J.S., Hoskin D.W. Bovine lactoferricin induces caspase-independent apoptosis in human B-lymphoma cells and extends the survival of immune-deficient mice bearing B-lymphoma xenografts // Exp. Mol. Pathol. - 2010. - Vol. 88(3). - P. 371-375. - DOI: 10.1016/j.yexmp.2010.02.001
Eike L.M., Yang N., Rekdal 0., Sveinbj0rnsson B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells // Oncotarget. - 2015. - Vol. 6(33). - P. 34910-34923. - DOI: 10.18632/oncotarget.5308
Camilio K.A., Berge G., Ravuri C.S., Rekdal O., Svein-bj0rnsson B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315 // Cancer Immunol Immunother. - 2014. - Vol. 63(6). - P. 601-613. - DOI: 10.1007/s00262-014-1540-0
Cheng W.D., Wold K.J., Bollinger L.B. et al. Supplementation With Lactoferrin and Lysozyme Ameliorates Environmental Enteric Dysfunction: A Double-Blind, Randomized, Placebo-Controlled Trial // Am J. Gastroenterol. - 2019. - Vol.114(4). - P. 671-678. - DOI: 10.14309/ajg.0000000000000170
Ramalingam S., Crawford J., Chang A. et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) // Ann Oncol. - 2013. - Vol. 24(11). - P. 2875-2880. - DOI: 10.1093/annonc/mdt371
Parikh P.M., Vaid A., Advani S.H. et al. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy // J. Clin. Oncol. -2011. - Vol. 29(31). - P. 4129-4136. - DOI: 10.1200/JCO.2010.34.4127
Hayes T.G., Falchook G.F., Varadhachary G.R. et al. Phase I trial of oral talactoferrin alfa in refractory solid tumors // Invest New Drugs. - 2006. - Vol. 24(3). - P. 233-240. - DOI: 10.1007/s10637-005-3690-6
Kozu T., Iinuma G., Ohashi Y et al. Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial // Cancer Prev. Res (Phila). - 2009. - Vol. 2(11). - P. 975-983. - DOI: 10.1158/1940-6207.CAPR-08-0208
Perez D., Sharples K.J., Broom R. et al. A randomised phase IIb trial to assess the efficacy of ReCharge ice cream in preventing chemotherapy-induced diarrhea // Support Care Cancer. - 2015. - Vol. 23(11). - P. 3307-3315. - DOI: 10.1007/s00520-015-2755-0
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2019